Anaplastic lymphomas and adenocarcinomas

Anaplastic lymphomas and adenocarcinomas

Since 1986, lung cancer has been the major killer of women and of all cancer patients on Taiwan.  Clinical studies show that 90% of female lung cancer patients do not smoke, and 85% of lung cancer patients suffer from non-small cell lung cancer or adenocarcinomas.  At time of detection, 70% of the patients are already in the late stage of lung cancer.

A doctor at the Taipei Veterans Hospital recommends targeted treatment using targeting medications to treat both anaplastic lymphomas and adenocarcinomas with gene therapy of the anaplastic lymphoma kinase (ALK) gene.

Chromosomal translocation is associated with anaplastic large cell lymphomas.  It creates a fusion made up of an ALK gene and a nucleophosmin gene.

In adenocarcinoma of the lung, an EML4-ALK fusion gene is responsible for non-small cell lung cancer or adenocarcinomas.  EML4 is the Echinoderm microtubule-associated protein-like 4, a protein encoded by the EML4 gene.  It is involved in cancers when spliced with the anaplastic lymphoma kinase (ALK) gene.

So far, Taiwan’s doctors still are not sure why more women who do not smoke get anaplastic large cell lymphomas as well as non-small cell adenocarcinomas of the lung.

The Economist Intelligence Unit’s quality of death ranking, end of life care report says that Taiwan ranks 14th in overall ranking, ahead of Singapore at 18th, Hong Kong at 20th, Japan at 23rd, South Korea at 32nd, Malaysia at 33rd, China at 37th and India at 40th.

In the basic end of life healthcare environment, Japan ranks 2nd, Taiwan ranks 15th, South Korea ranks 20th, Singapore ranks 30th, Hong Kong ranks 31st, China ranks 36th, and Malaysia ranks 37th.

In the availability of end of life care, Singapore ranks 16th, Taiwan ranks 19th, Malaysia ranks 22nd, Hong Kong ranks 24th, Japan ranks 28th, South Korea ranks 30th, India ranks 35th and China ranks 40th.

In the quality of end of life care with 40% weighting, Hong Kong ranks 8th, Taiwan ranks 10th, Singapore ranks 11th, Japan ranks 21st, Malaysia ranks 28th, South Korea ranks 29th, China ranks 35th and India ranks 37th.




About masterchensays

Victor Chen, herbalist, alternative healthcare lecturer, Chinese affairs analyst, retired journalist
This entry was posted in Uncategorized. Bookmark the permalink.